Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883905 · ClinicalTrials.gov registry record
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
A clinical trial of Acute Hepatic Porphyria, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- 150
- Enrollment target
- 20
- Study locations
NCT04883905 is a study of Acute Hepatic Porphyria that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04883905, a study of Acute Hepatic Porphyria, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Brussels
- Clinical Trial Site - Leuven
- Clinical Trial Site - Bordeaux
- Clinical Trial Site - Paris
- Clinical Trial Site - Toulouse
- Clinical Trial Site - Berlin
- Clinical Trial Site - Chemnitz
Alabama
- Clinical Trial Site - Birmingham
Arizona
- Clinical Trial Site - Gilbert
California
- Clinical Trial Site - San Francisco
Maryland
- Clinical Trial Site - Baltimore
Massachusetts
- Clinical Trial Site - Boston
Minnesota
- Clinical Trial Site - Minneapolis
New York
- Clinical Trial Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2027-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04883905
The ClinicalTrials.gov registry entry for NCT04883905 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Hepatic Porphyria appearing as the primary indexed condition, and to 0 interventions.
NCT04883905 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04883905 about?
NCT04883905 is a clinical study titled "ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)". This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
What is the current status of trial NCT04883905?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2021-04-26. Estimated completion is 2027-04-01.
What conditions does trial NCT04883905 study?
This clinical trial studies the following conditions: Acute Hepatic Porphyria.
Who is sponsoring clinical trial NCT04883905?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04883905 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Hepatic Porphyria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.